Demographic information
| ID | Duration | Auto-Ab | Age | Gender | Ethnicity | C peptide | BMI | HLA typing |
| yr | ng/ml | |||||||
| Recent onset cases | ||||||||
| Patient A | <1 wk | mIAA+ IA2ic+ | 9 | F | Caucasian | undetectable | N.D. | A2, 25 B8 DR3,4 |
| Patient B | 1 wk | mIAA+ GAD65+ IA2ic+ | 5 | M | Caucasian | undetectable | N.D. | A2, 25 B8, 60 DR3, 4 |
| Patient C | 10 wk | GAD65+ | 24 | M | Caucasian | 1.61 | 22.9 | A3,29 B7,44 DR7,13 |
| Patient D | 6 mo | IA2ic+ GAD65 + | 14 | F | Caucasian | 0.65 | 20.1 | A2, 25 B8 DR3, 3 |
| Patient E | 9 mo | GAD65+ IA2ic+ | 26 | F | Caucasian | 1.12 | 24.8 | A2,2 B18,44 DR3,4 |
| Longstanding cases | ||||||||
| Patient 1 | 1 yr | GAD65+ IA2ic+ | 17 | F | Caucasian | 0.9 | 21.2 | A2,25 B8 DR3,4 |
| Patient 2 | 1 yr | ICA512+ mIAA+ IA2ic+ | 12 | M | African American | 0.18 | 20.3 | A*0201, 6801 B*0602, 1502 DRB1*0901, 1602 DQA1*0102, 0301 DQAB1*0303, 0502 |
| Patient 3 | 3 yr | GAD65+ | 19 | M | Caucasian | 0.35 | 24.5 | A2,2 B18,44 DR3,3 |
| Patient 4 | 3 yr | GAD65+ | 19 | M | Caucasian | 1.2 | ND | A *0101, 0201, B*0801, 5101 DR*0301, 0404 |
| Patient 5 | 7 yr | ICA215+ mIAA+ IA-2ic+ | 22 | F | Caucasian | <0.05 | 21.6 | A*0201, 0205 B*3801, 5801 DRB1*1001, 1601 DQA1*0101, 0102 DQAB1*0501, 0502 |
| Patient 6 | 8 yr | ICA512+ ZnT8+ IA-2ic+ | 18 | F | Caucasian | <0.05 | 25.2 | A*0201, 0301 B*1501, 3901 DRB1*0101, 0401 DQA1*0101, 0301 DQAB1*0302, 0501 |
| ID | Duration | Auto-Ab | Age | Gender | Ethnicity | C peptide | BMI | HLA typing |
| yr | ng/ml | |||||||
| Recent onset cases | ||||||||
| Patient A | <1 wk | mIAA+ IA2ic+ | 9 | F | Caucasian | undetectable | N.D. | A2, 25 B8 DR3,4 |
| Patient B | 1 wk | mIAA+ GAD65+ IA2ic+ | 5 | M | Caucasian | undetectable | N.D. | A2, 25 B8, 60 DR3, 4 |
| Patient C | 10 wk | GAD65+ | 24 | M | Caucasian | 1.61 | 22.9 | A3,29 B7,44 DR7,13 |
| Patient D | 6 mo | IA2ic+ GAD65 + | 14 | F | Caucasian | 0.65 | 20.1 | A2, 25 B8 DR3, 3 |
| Patient E | 9 mo | GAD65+ IA2ic+ | 26 | F | Caucasian | 1.12 | 24.8 | A2,2 B18,44 DR3,4 |
| Longstanding cases | ||||||||
| Patient 1 | 1 yr | GAD65+ IA2ic+ | 17 | F | Caucasian | 0.9 | 21.2 | A2,25 B8 DR3,4 |
| Patient 2 | 1 yr | ICA512+ mIAA+ IA2ic+ | 12 | M | African American | 0.18 | 20.3 | A*0201, 6801 B*0602, 1502 DRB1*0901, 1602 DQA1*0102, 0301 DQAB1*0303, 0502 |
| Patient 3 | 3 yr | GAD65+ | 19 | M | Caucasian | 0.35 | 24.5 | A2,2 B18,44 DR3,3 |
| Patient 4 | 3 yr | GAD65+ | 19 | M | Caucasian | 1.2 | ND | A *0101, 0201, B*0801, 5101 DR*0301, 0404 |
| Patient 5 | 7 yr | ICA215+ mIAA+ IA-2ic+ | 22 | F | Caucasian | <0.05 | 21.6 | A*0201, 0205 B*3801, 5801 DRB1*1001, 1601 DQA1*0101, 0102 DQAB1*0501, 0502 |
| Patient 6 | 8 yr | ICA512+ ZnT8+ IA-2ic+ | 18 | F | Caucasian | <0.05 | 25.2 | A*0201, 0301 B*1501, 3901 DRB1*0101, 0401 DQA1*0101, 0301 DQAB1*0302, 0501 |
ICA512, islet cell autoantigen 512; ZnT8, zinc transporter 8; IA-2ic, intracytoplasmic domain of the tyrosine phosphatase IA-2; mIAA, micro assay for insulin autoantibodies; GAD65, Glutamic acid decarboxylase 65; ND, not determined